Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Quote | Passage Bio Inc. (NASDAQ:PASG)
Last: | $0.94 |
---|---|
Change Percent: | 0.0% |
Open: | $0.917 |
Close: | $0.94 |
High: | $1 |
Low: | $0.89 |
Volume: | 131,399 |
Last Trade Date Time: | 07/29/2024 03:00:00 am |
News | Passage Bio Inc. (NASDAQ:PASG)
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
Message Board Posts | Passage Bio Inc. (NASDAQ:PASG)
Subject | By | Source | When |
---|---|---|---|
So...anybody out there? Thoughts on upcoming abstract, etc? | catinhat | investorshub | 05/10/2022 7:16:39 PM |
PASG down from panic selling due to the | dealerschool2006 | investorshub | 01/22/2021 6:37:25 PM |
News, Short Squeeze, Breakout and More Instantly...
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Plan to initiate dosing of FTD-C9orf72 patients in 1H 2025 PHILADELPHIA, July 16, 2024 (...
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that William Chou, M.D., president and chief executive officer, will present at ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of i...